The core testing indicators and evidence-based grading of this whitepaper are derived from the group standard draft for comment, Clinical Testing Guidelines for Anti-Aging Medicine (T/FDSA), governed by the China Food and Drug Enterprises Quality and Safety Promotion Association (T/FDSA) and led by Beijing Geriatric Hospital (completed: July 15, 2026; planned release: September 19, 2026; planned implementation: October 7, 2026). TASCAP fully preserves the drafting organization, document number, and release / implementation milestones of the original standard, and recommends its evidence-based grading system to the Asia-Pacific region.
1. Background of the Original Standard
The Clinical Testing Guidelines for Anti-Aging Medicine (T/FDSA XXXX-2026) was proposed and led by Beijing Geriatric Hospital, with the draft-for-comment version completed on July 15, 2026, and scheduled for release on September 19, 2026 and implementation on October 7, 2026. This standard fills a gap in China's standards for selecting anti-aging clinical testing items, evidence-based grading, and report interpretation.
2. Core Assessment Model: Age Deviation
AgeDev = BA − CAWhen AgeDev ≥ 0, the body is in a state of accelerated biological aging; when AgeDev < 0, the body is in a state of slower biological aging.
3. Three-Tier Evidence-Based Testing Map
3.1 Strongly Recommended Tests
| Test Category | Specific Indicators | Clinical Relevance for Anti-Aging Assessment |
|---|---|---|
| Routine blood, urine, and stool | CBC (including RDW), urinalysis + ACR, stool routine + FIT | Elevated RDW is associated with increased all-cause mortality; ACR reflects early renal injury and endothelial dysfunction. |
| Comprehensive biochemistry | Liver function, renal function (Scr, CysC, eGFR), glucose metabolism (FPG, HbA1c), lipids, electrolytes | CysC is more sensitive than creatinine; HbA1c reflects 2–3 months of glycemic control and metabolic aging; each 1 mmol/L reduction in LDL-C lowers cardiovascular events by 22%. |
| Metabolism and inflammation | Fasting insulin, HOMA-IR, hs-CRP, IL-6, TNF-α, ESR | HOMA-IR ≥ 2.5 indicates insulin resistance; hs-CRP and IL-6 reflect systemic chronic low-grade inflammation (Inflammaging). |
| Full hormone panel | TSH, FT4, FT3, cortisol, E2, T, FSH, LH, DHEA-S, IGF-1 | DHEA-S declines significantly with age, reflecting adrenal reserve; each 1 SD decrease in IGF-1 raises cardiovascular mortality by 27%. |
| Nutritional status | 25-OH-D, folate, vitamin B12, homocysteine (Hcy) | All-cause mortality risk increases by 35% in those deficient in 25-OH-D (<20 ng/mL); Hcy > 15 μmol/L is an independent risk factor for cardiovascular disease and cognition. |
3.2 Conditionally Recommended Tests
- Cardiovascular system: NT-proBNP, hs-TnI, lipoprotein (a) (Lp(a) > 50 mg/dL is an independent ASCVD risk).
- Cancer screening: routine tumor markers (CEA, AFP, CA19-9, PSA, etc.), DNA methylation tumor liquid biopsy for early screening, polygenic risk score (PRS), and hereditary cancer genetic testing (BRCA1/2, Lynch syndrome).
- Metabolism and microbiome: OGTT and insulin release test, ceramide, metabolomics, and gut microbiome (16S / metagenomics).
- Hereditary genes: APOE genotyping (APOE ε4 heterozygotes have a 3–4× increased Alzheimer's risk, homozygotes a 12× increase).
3.3 Tests with Application Prospects (Requiring Evidence)
- DNA methylation clock (Horvath, PhenoAge, GrimAge, DunedinPACE), telomere length (qPCR T/S ratio), SASP senescence factors (MMP-9, p16, p21).
- Immune senescence markers (CD28null CD8+ T cells > 40% indicates immune senescence), mitochondrial function (mtDNA/nDNA, 8-OHdG), NAD+ levels.
- Autophagy function (LC3-II/LC3-I), skin advanced glycation end products (AGEs/SAF), nuclear envelope function (Lamin B1/cGAS-STING), and TMAO.
4. Quality Control and Reporting Standards
Internal quality control using Westgard rules must be performed daily; omics projects must use reference materials of known biological age for inter-batch quality control; external quality assessment (EQA/PT) participation is mandatory. Routine reports are issued within 5–7 working days; genetic and methylation projects within 10–15 working days.
5. TASCAP Statement
The copyright of the original standard Clinical Testing Guidelines for Anti-Aging Medicine belongs to the China Food and Drug Enterprises Quality and Safety Promotion Association (T/FDSA) and the drafting organization, Beijing Geriatric Hospital.